Leesa Gentry - Mar 1, 2024 Form 3 Insider Report for RenovoRx, Inc. (RNXT)

Role
Chief Clinical Officer
Signature
/s/ Leesa Gentry
Stock symbol
RNXT
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
3
Date filed
3/8/2024, 04:26 PM
Next filing
Mar 8, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RNXT Options Mar 1, 2024 Common Stock 62.5K $2.11 Direct F1
holding RNXT Options Mar 1, 2024 Common Stock 19.4K $1.08 Direct F2
holding RNXT Options Mar 1, 2024 Common Stock 60.2K $1.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 10-year incentive stock options granted to the reporting person on June 1, 2023 pursuant to Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). One-fourth of the shares subject to the option vest on April 10, 2024 and 1/36th of the remaining shares vest monthly thereafter.
F2 Represents 10-year stock non-qualified stock options granted to the reporting person on January 19, 2024 pursuant to the Plan as a bonus. These options were fully vested upon issuance.
F3 Represents 10-year stock incentive stock options granted to the reporting person on January 19, 2024 pursuant to the Plan. These options vest at a rate of 1/48 per month beginning on February 1, 2024.